ఇండెక్స్ చేయబడింది
  • అకడమిక్ జర్నల్స్ డేటాబేస్
  • J గేట్ తెరవండి
  • జెనామిక్స్ జర్నల్‌సీక్
  • JournalTOCలు
  • చైనా నేషనల్ నాలెడ్జ్ ఇన్‌ఫ్రాస్ట్రక్చర్ (CNKI)
  • స్కిమాగో
  • ఉల్రిచ్ పీరియాడికల్స్ డైరెక్టరీ
  • RefSeek
  • హమ్దార్డ్ విశ్వవిద్యాలయం
  • EBSCO AZ
  • OCLC- వరల్డ్ క్యాట్
  • పబ్లోన్స్
  • మియార్
  • యూనివర్సిటీ గ్రాంట్స్ కమిషన్
  • జెనీవా ఫౌండేషన్ ఫర్ మెడికల్ ఎడ్యుకేషన్ అండ్ రీసెర్చ్
  • యూరో పబ్
  • గూగుల్ స్కాలర్
ఈ పేజీని భాగస్వామ్యం చేయండి

నైరూప్య

Burden of Pneumococcal Disease: An 8-Year Retrospective Analysis of Local Surveillance Data from Three Regions in Uganda (2012-2020)

Ikiriza Antony*, John Rubaihayo, Innocent Atuhe, Alphonsina Mujawimana, David Ndungutse

Background: Pneumococcal disease is a leading preventable cause of childhood diseases and deaths globally with many of the deaths occurring in low and middle-income countries. In Uganda, Pneumococcal Conjugate Vaccine 13 vaccination campaign was rolled out in 2014 yet data on vaccination coverage, prevalence of pneumococcal disease in children <5 years are scarce. This study therefore evaluated the pneumococcal disease burden following pneumococcal conjugate vaccination campaign in Uganda.

Methods: This was an eight year retrospective analysis of pneumococcal surveillance data recorded from 3 regions of Uganda (namely Kigezi region in South Western Uganda, Busoga region in Eastern Uganda and Tooro region in Mid-western Uganda) during January 2012-December 2020. Demographic and clinical diagnosis data were abstracted from medical records at three regional referral hospitals representing the 3 regions to assess disease burden before and after introduction of the Pneumococcal conjugate vaccine (PVC 13) in Uganda. Data were summarized by demographic characteristics and geographical location of study subjects.

Results: Pre-vaccination period had a prevalence of 59.4% of the cases while the post-vaccination period had 40.6% prevalence rate. By region, prevalence was highest in Kigezi (52.1%) followed by Tooro (32.6%) and lowest in Busoga at (15.3%).

In these settings, immunological serotyping was never done and data on most risk factors were missing. The prevalence of pediatric pneumococcal infections remains high even after vaccination campaign calling for a review of the vaccination strategy.

Conclusion and recommendations: Pneumococcal disease burden was still high (40.6%) despite pneumococcal vaccination roll out. The highest prevalence of pneumococcal disease was in children under 24 months old. However, local surveillance capacity needs to be strengthened to capture data on pneumococcal serotypes and pneumococcal disease risk factors.

నిరాకరణ: ఈ సారాంశం ఆర్టిఫిషియల్ ఇంటెలిజెన్స్ టూల్